HR status in determining the efficacy of platinum therapy in advanced TNBC

TNBC: Updated Efficacy Results From IMpassion130Подробнее

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant TherapyПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Olaparib + durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced TNBCПодробнее

DORA: durvalumab and olaparib in platinum treated advanced TNBCПодробнее

Neelima Denduluri, MD -- Treatment of Triple Negative Breast CancerПодробнее

Dr. Tolaney on Platinum-Based Therapy in Neoadjuvant Setting of TNBCПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Enhancing triple negative breast cancer treatment with immunotherapy across all settingsПодробнее

Harnessing the Immune System in the Treatment of Triple-Negative Breast CancerПодробнее

Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in Triple-Negative Breast CancerПодробнее

Patient Selection for Eribulin in Breast CancerПодробнее

Targeting Advanced Triple-Negative Breast Cancer | Dana-Farber Cancer InstituteПодробнее

Sudeep Gupta, SABCS 2022: Addition of platinum to chemotherapy in triple-negative breast cancerПодробнее

KEYNOTE-355: pembro + chemo in triple-negative breast cancerПодробнее

The association between JNK activity and immunotherapeutic efficacy of IO in TNBCПодробнее

Triple Negative Breast Cancer - O'ReganПодробнее

New study identifies promising drug combinations for triple negative breast cancer treatmentПодробнее